Sanofi Gains FDA Priority Review for Venglustat in Gaucher Disease Type 3

For regulatory affairs leads tracking rare neurological disease pathways, Sanofi's venglustat has cleared a significant procedural threshold: the FDA has accepted the New Drug Application (NDA) for Priority Review, setting a PDUFA target action date of 25 November 2026 for the oral glucosylceramide synthase inhibitor (GCSi) in Gaucher disease type 3 (GD3).

GD3 is a rare lysosomal storage disorder in which glycosphingolipid accumulation extends into the central nervous system, driving neuroinflammation and progressive manifestations including cognitive deficits and ataxia. No approved therapy currently addresses the neurological component of GD3 in the United States. Venglustat's ability to cross the blood-brain barrier positions it as a mechanistically distinct candidate relative to existing enzyme replacement therapies (ERT).

The NDA is supported by the Phase 3 LEAP2MONO study (NCT05222906), a double-blind, active-comparator trial enrolling adults and paediatric patients aged 12 and older with GD3 neurological manifestations who had previously achieved systemic stabilisation on ERT. Data presented at WORLDSymposium 2026 showed venglustat met both co-primary endpoints and three of four key secondary endpoints. The most frequently reported adverse events were headache (14.3% venglustat vs. 18.2% ERT), nausea (14.3% vs. 4.5%), splenomegaly (14.3% vs. 0%), and diarrhoea (14.3% vs. 0%); no new safety signals emerged relative to prior studies.

From a regulatory strategy standpoint, venglustat carries a layered designation profile relevant to teams managing orphan and accelerated pathways. The compound holds Breakthrough Therapy and Fast Track designations from the FDA for GD3, alongside Orphan Drug designation in the US, EU, and Japan. A parallel regulatory review is active in the EU, with Sanofi indicating further global submissions are planned through 2026. The combination of Breakthrough Therapy designation and Priority Review compresses the standard review timeline from twelve to six months, a sequencing that QA and regulatory operations teams will need to factor into pre-approval inspection readiness planning.

If approved, venglustat would represent the first US-authorised treatment specifically targeting the neurological manifestations of GD3, expanding the therapeutic options available within Sanofi's lysosomal storage disease portfolio.

The November 2026 PDUFA date marks the next measurable checkpoint, with pre-approval inspection scheduling and labelling negotiations likely to define the critical path between now and a potential market authorisation.

Source: Sanofi via GlobeNewswire, 28 May 2026.